PDCD1 and cancer: The immune cell profiling of peripheral blood in cancer patients administered with anti-PD1 immunotherapy is ongoing and will explore the impact of PD-1 engagement on NK cells, thus providing essential information on the matter (NCT02535247 and NCT01714739).